Replies to post #15113 on Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

Where do start...LOL

55

Ifenprodil HAS made it to Human testing and completed a Phase 2 CT.

True, Ifenprodil has completed a Phase 2 clinical trial that completed a Phase 3 clinical trial and was approved. That would be the current Ifenprodil being sold in Japan. As to a "Phase 2" clinical trial for Ifenprodil under the control of Algernon - I BEG TO DIFFER. Algernon has not conducted any Phase 2 clinical trials to date worthy of being called a Phase 2. Algernon has thus far completed 1 COVID-19 "study" that was not designed for statistical significance. I don't know how many times that needs to be said but this is the millionth and one time.

55

With the refund cash in the bank there should be no immediate need for more cash until some results for the applications are seen.

Dude, the company reported cash on hand at $3.5M CAD. That equates to $2.83M USD. That's less than $3 Mil to run 3 stat sig clinical trials -2 in the USA and 1 in Europe. I'd love to see your math on the cost breakdown of those 3 clinical trials being run simultaneously.

55

The INDs are supported by completed studies for the NEW proposed 'Indications'.

I disagree with the so-called "study" for Chronic Cough. What Algernon is going off of is the preclinical work it already did that showed Ifenprodil outperformed the #1 competitor by 110%. It';s that data that n]makes the Chronic Cough angle a worthy cause. What management would have you believe is an obscure "study" in Australia and New Zealand that's bogged down with recruitment has provided the company with much needed data BEFORE full enrollment of 20 FRIGGIN people suddenly provided needed data to move forward with a standalone Chronic Cough clinical trial. That's straight up Bullshit! It's bullshit for the multitude of reasons I already explained here to exhaustion.

55

Ifenprodil has already passed a DSMB Safety review for a Phase 2 CT.

Yeah, and look at what the DSMB recommendation got Algernon in the end. More Bullshit. No Statistical Significance butr DSMB said yeah sure - GO FOR IT! Meanwhile, in FDA World. Hey Christopher Moreau, show us the letter from the FDA that your shareholders paid for in blood.

55

Any application to up-list will take time.

Basically, you have thanked smoki for posting the NASDAQ uplist information without actually reading through it. There is a timeline my friend and it ain't a long time. Go check it - Due Diligence.

55

IND approval timeline is hard to figure. AGN is requesting three different pre-IND meetings.

See previous reply regarding NASDAQ uplisting. All this stuff has finite timelines and ALL will be resolved well before Year End 2021.

55

I am betting against your scenario and that there wont be a R/S before a PPS recovery.** Nasdaq 2022...GLTA...

You mean like those other COVID-19 penny stock plays ur chasing?

55

**if a R/S is needed at all!!!

Correct, "IF"



IF management is hellbent on uplisting to NASDAQ anytime before the stock hits dollarsville a reverse split will be mandatory. Again, you need to read the NASDAQ uplist requirements - Due Diligence.

Chris probably makes for a good beer buddy, but not a good CEO.

Tell beer buddy I said hello.

Peace,

M$